metricas
covid
Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 ca...
Journal Information
Vol. 159. Issue 7.
Pages 344-346 (October 2022)
Share
Share
Download PDF
More article options
Visits
5
Vol. 159. Issue 7.
Pages 344-346 (October 2022)
Clinical report
Effectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases
Efectividad de belimumab en el tratamiento de la nefritis lúpica: análisis de 8 casos
Visits
5
Marta de la Rubia Navarro
Corresponding author
mardena@mail.ucv.es

Corresponding author.
, José Rafael Ivorra Cortés, Elena Grau García, José Andrés Román Ivorra
Servicio de Reumatología, Hospital Universitari i Politècnic La Fe, Valencia, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract
Background and objective

Belimumab is a monoclonal antibody targeting BLyS approved for Systemic Lupus Erythematosus (SLE), with recent indication for lupus nephritis (LN).

To analyze effectiveness of Belimumab in LN patients.

Methods

Retrospective and cross-sectional study including SLE patients (SLICC/ACR 2012 criteria) with LN demonstrated by kidney biopsy, treated with Belimumab. A clinical history review was made and serological data, kidney function and urine sediment were collected.

Results

Eight patients with LN demonstrated by kidney biopsy were included. Median age was 37.56 (7.03) years, with 15.13 (8.71) years since SLE diagnosis was made and 4.61 (2.64) years since onset of belimumab.

Proteinuria was reduced to normal values in 6 patients, and renal function was stable from the beginning of treatment in all cases. There was a reduction in the anti-DNA level and normalization of complement in those cases in which it was reduced. One patient presented an increase in anti-DNA titer, with normal complement.

Conclusions

In clinical practice, belimumab can improve LN in terms of serological activity, kidney function and urine sediment.

Keywords:
Lupus nephritis
Belimumab
Resumen
Introducción y objetivo

Belimumab es un anticuerpo monoclonal aprobado para pacientes con lupus eritematoso sistémico (LES), con indicación reciente para nefritis lúpica (NL).

El objetivo es analizar la eficacia de Belimumab en pacientes con NL.

Métodos

Estudio transversal, retrospectivo, que incluye pacientes diagnosticados de LES (criterios SLICC/ACR 2012), con nefritis demostrada mediante biopsia, tratados con Belimumab. Se recogieron datos serológicos, función renal (creatinina, filtrado glomerular) y sedimento urinario.

Resultados

Se incluyen 8 pacientes con edad media de 37,56 (7,03) años, con 15,13 (8,71) años de evolución de la enfermedad y 4,61 (2,64) años desde el inicio de belimumab.

La proteinuria se redujo hasta alcanzar valores normales en 6 pacientes, manteniéndose la función renal estable desde el inicio del tratamiento en todos los casos. Se registró una reducción del nivel de anti-DNA y una normalización del complemento en los casos en que estaba reducido. En uno de los pacientes se registró un aumento del título de anti-DNA, manteniéndose el complemento normal.

Conclusiones

En práctica clínica real, belimumab puede mejorar la NL en términos de actividad serológica, función renal y sedimento urinario.

Palabras clave:
Nefritis lúpica
Belimumab

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2023.03.033
No mostrar más